AP-1/c-Jun transcription factors: regulation and function in malignant melanoma

Melanie Kappelmann1, Anja Bosserhoff1, Silke Kuphal1

  • 1Institute of Pathology, Molecular Pathology, University of Regensburg, Germany.

Insights

The transcription factor c-Jun drives malignant melanoma progression through diverse regulatory pathways. Understanding these molecular mechanisms is key to targeting this aggressive skin cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Malignant melanoma incidence is rising globally.
  • Transcription factors, like Activator Protein-1 (AP-1), are crucial in melanoma development.
  • The AP-1 family member c-Jun is highly expressed and active in melanoma cells.

Purpose of the Study:

  • To investigate the diverse molecular mechanisms regulating c-Jun expression and activity in malignant melanoma.
  • To understand the role of c-Jun in melanoma progression and development.
  • To explore novel regulatory pathways beyond mitogen-activated protein kinases (MAPKs).

Main Methods:

  • Analysis of melanoma-relevant signaling pathways.
  • Investigation of transcription factor regulation.
  • Review of recent studies on c-Jun regulation by miRNAs and cytoskeleton.

Main Results:

  • c-Jun is a key driver of AP-1 activity in melanoma.
  • c-Jun is regulated by multiple pathways, including MAPKs, miRNAs, and the cytoskeleton.
  • While c-Jun often has oncogenic functions, other AP-1 proteins can be anti-oncogenic.

Conclusions:

  • Diverse regulatory mechanisms control c-Jun expression and activity, contributing to melanoma progression.
  • The heterogeneity of tumor types, especially melanoma, accounts for this complex regulatory machinery.
  • Targeting c-Jun and its regulatory pathways offers potential therapeutic strategies for malignant melanoma.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.2K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K